Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|September 22, 2001
How contraceptive use patterns differ by pregnancy intention: implications for counselingR Petersen, J A Gazmararian, K Anderson Clark, et al.American Journal of Cancer Research|May 18, 2016
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrierAndreas Machl, Erik W Wilker, Hui Tian, et al.Free Radical Biology & Medicine|March 30, 2016
Synthesis, evaluation, and metabolism of novel [6]-shogaol derivatives as potent Nrf2 activatorsYingdong Zhu, Pei Wang, Yantao Zhao, et al.Molecular Cancer Therapeutics|March 31, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET AlterationsJoachim Albers, Manja Friese-Hamim, Anderson Clark, et al.Lung Cancer (Amsterdam, Netherlands)|December 23, 2021
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastasesManja Friese-Hamim, Anderson Clark, Dominique Perrin, et al.Scientific Reports|November 21, 2023
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignanciesSamantha M Goodstal, Jing Lin, Timothy Crandall, et al.Scientific Reports|September 25, 2023
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumabShota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, et al.Molecular Cancer Therapeutics|September 27, 2012
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenograftsAngela Romanelli, Anderson Clark, Franck Assayag, et al.Journal of Medicinal Chemistry|October 1, 2021
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered CancersLizbeth DeSelm, Bayard Huck, Ruoxi Lan, et al.Bioorganic & Medicinal Chemistry Letters|September 5, 2021
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitorsYufang Xiao, Bayard R Huck, Ruoxi Lan, et al.Pageof 1